Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults — Stella

Home/Recurrent Atypical/malignant Meningioma/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Atypical/malignant Meningioma trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Sanbo Brain Hospital, Beijing, Beijing Municipality

Key details

Sponsor

Beijing Sanbo Brain Hospital

Enrollment target

~29 participants

Started

August 2020

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.